Disease & disorder

triple-positive breast carcinoma

MONDO:0700078

A breast carcinoma which is positive for expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).

Clinical trials1

Recruiting0

Drug concepts studied1

Synonyms3

Disease research snapshot

CureCurrent currently links 1 distinct registered clinical trials to triple-positive breast carcinoma through its MONDO disease mappings. 0 of those studies have the registry status “recruiting” (0%). These are registry statuses, not availability guarantees, study results or evidence of effectiveness.

The leading sponsor shown in this linked dataset is Shengjing Hospital, associated with 1 distinct linked trials. This is a count of records, not a ranking of the sponsor's scientific quality.

The highest-count mapped research city in the current result is Shenyang, China. Only site locations available in the published registry projection are counted; some trial sites may be missing or outdated.

The most frequently mapped drug concept in the current linked trials is letrozole (1 distinct trials). This describes what has been studied, not a recommended treatment.

Numbers are derived from CureCurrent's current ClinicalTrials.gov projection and conservative MONDO/RxNorm mappings. See sources, counting rules and limitations and verify eligibility or clinical findings with the original study record.

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.